Atrinsic (PTIX) Competitors

$0.62 0.00 (0.00%)

As of 05/22/2026

PTIX vs. FLGC, PULM, ENVB, RVPH, and CAPS

Should you buy Atrinsic stock or one of its competitors? MarketBeat compares Atrinsic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atrinsic include Flora Growth (FLGC), Pulmatrix (PULM), Enveric Biosciences (ENVB), Reviva Pharmaceuticals (RVPH), and Capstone Therapeutics (CAPS). These companies are all part of the "pharmaceutical products" industry.

How does Atrinsic compare to Flora Growth?

Flora Growth (NASDAQ:FLGC) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 8.0% of Atrinsic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Atrinsic has lower revenue, but higher earnings than Flora Growth. Atrinsic is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

In the previous week, Flora Growth had 1 more articles in the media than Atrinsic. MarketBeat recorded 1 mentions for Flora Growth and 0 mentions for Atrinsic. Flora Growth's average media sentiment score of 0.90 beat Atrinsic's score of 0.00 indicating that Flora Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Flora Growth	Positive
Atrinsic	Neutral

Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Flora Growth presently has a consensus price target of $30.00, suggesting a potential upside of 601.75%. Given Flora Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Flora Growth is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Atrinsic's return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Atrinsic	N/A	N/A	-379.72%

Summary

Flora Growth beats Atrinsic on 9 of the 15 factors compared between the two stocks.

How does Atrinsic compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic's return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-107.84%	-91.58%
Atrinsic	N/A	N/A	-379.72%

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 8.0% of Atrinsic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Pulmatrix's average media sentiment score of 0.00 equaled Atrinsic'saverage media sentiment score.

Company	Overall Sentiment
Pulmatrix	Neutral
Atrinsic	Neutral

Pulmatrix has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Pulmatrix has higher revenue and earnings than Atrinsic. Pulmatrix is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.63	-$5.16M	-$1.23	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Summary

Pulmatrix beats Atrinsic on 6 of the 9 factors compared between the two stocks.

How does Atrinsic compare to Enveric Biosciences?

Atrinsic (NASDAQ:PTIX) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Atrinsic is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Atrinsic has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Enveric Biosciences had 3 more articles in the media than Atrinsic. MarketBeat recorded 3 mentions for Enveric Biosciences and 0 mentions for Atrinsic. Enveric Biosciences' average media sentiment score of 0.37 beat Atrinsic's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
Enveric Biosciences	Neutral

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Atrinsic's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Enveric Biosciences	N/A	-220.97%	-177.47%

Summary

Atrinsic and Enveric Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Atrinsic compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Atrinsic's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Atrinsic	N/A	N/A	-379.72%

Reviva Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Atrinsic has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Atrinsic. MarketBeat recorded 1 mentions for Reviva Pharmaceuticals and 0 mentions for Atrinsic. Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled Atrinsic'saverage media sentiment score.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Atrinsic	Neutral

Atrinsic is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 8.0% of Atrinsic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential upside of 16,042.05%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Reviva Pharmaceuticals beats Atrinsic on 7 of the 12 factors compared between the two stocks.

How does Atrinsic compare to Capstone Therapeutics?

Atrinsic (NASDAQ:PTIX) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Capstone Therapeutics had 4 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for Capstone Therapeutics and 0 mentions for Atrinsic. Atrinsic's average media sentiment score of 0.00 beat Capstone Therapeutics' score of -0.75 indicating that Atrinsic is being referred to more favorably in the media.

Company	Overall Sentiment
Atrinsic	Neutral
Capstone Therapeutics	Negative

Atrinsic has higher earnings, but lower revenue than Capstone Therapeutics. Atrinsic is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Capstone Therapeutics	$48.11M	0.10	-$21.23M	-$3.37	N/A

Atrinsic has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.52, suggesting that its share price is 252% less volatile than the broader market.

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Atrinsic has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Atrinsic's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Atrinsic beats Capstone Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTIX vs. The Competition

Export

Metric	Atrinsic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.12M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.08	18.74	21.00	25.66
Price / Sales	N/A	323.98	562.18	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.32	7.09	10.41	7.14
Net Income	-$5.53M	$24.45M	$3.57B	$335.98M
7 Day Performance	-4.99%	6.38%	6.40%	4.11%
1 Month Performance	-23.77%	2.43%	3.54%	2.52%
1 Year Performance	-87.03%	62.98%	34.14%	35.04%

Atrinsic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTIX Atrinsic	N/A	$0.62 flat	N/A	-87.0%	$1.12M	N/A	N/A	2
FLGC Flora Growth	2.282 of 5 stars	$4.44 -17.0%	$30.00 +575.7%	-84.4%	$4.64M	$57.61M	N/A	280	Gap Up
PULM Pulmatrix	0.2343 of 5 stars	$1.27 flat	N/A	-80.3%	$4.64M	N/A	N/A	20	Gap Up
ENVB Enveric Biosciences	0.3212 of 5 stars	$2.29 -6.1%	N/A	-85.6%	$4.56M	N/A	N/A	20	Analyst Upgrade
RVPH Reviva Pharmaceuticals	2.2757 of 5 stars	$0.35 -2.0%	$66.67 +19,218.1%	-98.0%	$4.42M	N/A	N/A	5	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTIX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atrinsic (PTIX) Competitors

PTIX vs. FLGC, PULM, ENVB, RVPH, and CAPS

How does Atrinsic compare to Flora Growth?

Summary

How does Atrinsic compare to Pulmatrix?

Summary

How does Atrinsic compare to Enveric Biosciences?

Summary

How does Atrinsic compare to Reviva Pharmaceuticals?

Summary

How does Atrinsic compare to Capstone Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atrinsic (PTIX) Competitors

PTIX vs. FLGC, PULM, ENVB, RVPH, and CAPS

How does Atrinsic compare to Flora Growth?

Do insiders and institutionals hold more shares of FLGC or PTIX?

Which has higher valuation and earnings, FLGC or PTIX?

Does the media refer more to FLGC or PTIX?

Which has more volatility & risk, FLGC or PTIX?

Do analysts prefer FLGC or PTIX?

Is FLGC or PTIX more profitable?

Summary

How does Atrinsic compare to Pulmatrix?

Do analysts rate PULM or PTIX?

Is PULM or PTIX more profitable?

Do insiders & institutionals hold more shares of PULM or PTIX?

Does the media refer more to PULM or PTIX?

Which has more risk and volatility, PULM or PTIX?

Which has preferable earnings & valuation, PULM or PTIX?

Summary

How does Atrinsic compare to Enveric Biosciences?

Which has better earnings & valuation, PTIX or ENVB?

Which has more volatility & risk, PTIX or ENVB?

Do analysts recommend PTIX or ENVB?

Does the media prefer PTIX or ENVB?

Do institutionals and insiders hold more shares of PTIX or ENVB?

Is PTIX or ENVB more profitable?

Summary

How does Atrinsic compare to Reviva Pharmaceuticals?

Is RVPH or PTIX more profitable?

Which has more risk and volatility, RVPH or PTIX?

Does the media refer more to RVPH or PTIX?

Which has stronger valuation & earnings, RVPH or PTIX?

Do insiders and institutionals believe in RVPH or PTIX?

Do analysts recommend RVPH or PTIX?

Summary

How does Atrinsic compare to Capstone Therapeutics?

Does the media favor PTIX or CAPS?

Which has stronger earnings and valuation, PTIX or CAPS?

Which has more volatility & risk, PTIX or CAPS?

Do institutionals & insiders have more ownership in PTIX or CAPS?

Is PTIX or CAPS more profitable?

Do analysts rate PTIX or CAPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools